Optomed Oyj

Symbol: OPTOMED.HE

HEL

5.36

EUR

Market price today

  • -20.1682

    P/E Ratio

  • 4.2353

    PEG Ratio

  • 95.28M

    MRK Cap

  • 0.00%

    DIV Yield

Optomed Oyj (OPTOMED-HE) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.68%

Operating Profit Margin

-0.26%

Net Profit Margin

-0.29%

Return on Assets

-0.15%

Return on Equity

-0.22%

Return on Capital Employed

-0.17%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO:Mr. Juho Himberg
Full-time employees:114
City:Oulu
Address:Yrttipellontie 1
IPO:2019-12-05
CIK:

Optomed Oyj, a medical technology company, manufactures and sells handheld fundus cameras and screening software in Finland, China, and internationally. The company operates through two segments, Devices and Software segments. The company develops, manufactures, and sells fundus camera products, which are used by ophthalmologists, pediatricians, endocrinologists, neurologists, and primary care professionals. It offers camera products under the Optomed Smartscope Pro, Optomed Aurora, Optomed Polaris, and Optomed Halo brands, as well as OEM cameras, including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal brand names. The company also provides Avenue Eye Screen, a workflow management software for screening and monitoring of eye diseases, such as diabetic retinopathy; Avenue Archive, an application software for displaying, archiving, and transmitting healthcare information; Avenue Telemedicine, a telemedicine solution for remote image analysis; Avenue AI, an automated diabetic retinopathy screening service; and Avenue Sync, a software solution for integrating fundus camera to the hospital image archive and worklist server. In addition, it offers Avenue Cancer Screen, a screening process management software for breast, cervical, and colorectal cancer; Optomed RIS, a software solution for healthcare imaging units for enhancing the diagnostic process and treatment decisions; Sectra PACS, a modular system optimized for use by high production healthcare providers; Optomed Service Portal, a support function for healthcare units that order and produce imaging services; Facad, a tracing software for visible light imaging and cephalometric measurements; and Sectra PACS Pathology, a digital pathology solution, which allows scanned glass slides to be distributed and diagnosed. Further, the company provides professional IT consulting services for government institutions. It sells its products and solutions through OEMs, distributors, and direct sales. The company's customers include hospitals, eye clinics, and optician chains and stores. The company was incorporated in 2004 and is headquartered in Oulu, Finland.

General Outlook

When we look at how much money they make before expenses, they keep 0.678% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.263%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.294%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.153% return, is a testament to Optomed Oyj's adeptness in optimizing resource deployment. Optomed Oyj's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.223%. Furthermore, the proficiency of Optomed Oyj in capital utilization is underscored by a remarkable -0.165% return on capital employed.

Stock Prices

Optomed Oyj's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $3.63, while its low point bottomed out at $3.47. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Optomed Oyj's stock market.

Liquidity Ratios

Analyzing OPTOMED.HE liquidity ratios reveals its financial health of the firm. The current ratio of 259.86% gauges short-term asset coverage for liabilities. The quick ratio (204.04%) assesses immediate liquidity, while the cash ratio (140.89%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio259.86%
Quick Ratio204.04%
Cash Ratio140.89%

Profitability Ratios

OPTOMED.HE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -29.93% underscores its earnings before tax deductions. The effective tax rate stands at 1.77%, revealing its tax efficiency. The net income per EBT, 98.23%, and the EBT per EBIT, 113.74%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -26.32%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-29.93%
Effective Tax Rate1.77%
Net Income per EBT98.23%
EBT per EBIT113.74%
EBIT per Revenue-26.32%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.60, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 473.35% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding204
Days of Inventory Outstanding212
Operating Cycle289.03
Days of Payables Outstanding267
Cash Conversion Cycle22
Receivables Turnover4.73
Payables Turnover1.37
Inventory Turnover1.72
Fixed Asset Turnover6.92
Asset Turnover0.52

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.04, and free cash flow per share, -0.18, depict cash generation on a per-share basis. The cash per share value, 0.43, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.04, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.04
Free Cash Flow per Share-0.18
Cash per Share0.43
Operating Cash Flow Sales Ratio-0.04
Free Cash Flow to Operating Cash Flow Ratio5.03
Cash Flow Coverage Ratio-0.12
Short Term Coverage Ratio-0.40
Capital Expenditure Coverage Ratio-0.25
Dividend Paid and Capex Coverage Ratio-0.25

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 16.71%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.24, we discern the balance between debt and equity financing. The long-term debt to capitalization, 14.15%, and total debt to capitalization, 19.26%, ratios shed light on its capital structure. An interest coverage of -3.88 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio16.71%
Debt Equity Ratio0.24
Long Term Debt to Capitalization14.15%
Total Debt to Capitalization19.26%
Interest Coverage-3.88
Cash Flow to Debt Ratio-0.12
Company Equity Multiplier1.43

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.90, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.27, reflects the portion of profit attributed to each share. The book value per share, 1.22, represents the net asset value distributed per share, while the tangible book value per share, 0.40, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.90
Net Income Per Share-0.27
Book Value Per Share1.22
Tangible Book Value Per Share0.40
Shareholders Equity Per Share1.22
Interest Debt Per Share0.35
Capex Per Share-0.14

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 3.00%, indicates top-line expansion, while the gross profit growth, 11.19%, reveals profitability trends. EBIT growth, 14.92%, and operating income growth, 14.92%, offer insights into operational profitability progression. The net income growth, 18.84%, showcases bottom-line expansion, and the EPS growth, 27.03%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth3.00%
Gross Profit Growth11.19%
EBIT Growth14.92%
Operating Income Growth14.92%
Net Income Growth18.84%
EPS Growth27.03%
EPS Diluted Growth27.03%
Weighted Average Shares Growth14.11%
Weighted Average Shares Diluted Growth14.11%
Operating Cash Flow Growth74.05%
Free Cash Flow Growth43.93%
5-Year Revenue Growth per Share-17.56%
3-Year Revenue Growth per Share-7.87%
5-Year Operating CF Growth per Share-538.99%
3-Year Operating CF Growth per Share82.57%
5-Year Net Income Growth per Share-176.56%
3-Year Net Income Growth per Share-10.97%
5-Year Shareholders Equity Growth per Share189.54%
3-Year Shareholders Equity Growth per Share-19.47%
Receivables Growth-30.17%
Inventory Growth-5.94%
Asset Growth-7.10%
Book Value per Share Growth-12.28%
Debt Growth-27.95%
R&D Expense Growth-36.29%
SGA Expenses Growth102.97%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 61,558,860.56, captures the company's total value, considering both debt and equity. Income quality, 0.14, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.17, gauges operational efficiency, while the research and development to revenue, 1.52%, highlights investment in innovation. The ratio of intangibles to total assets, 47.27%, indicates the value of non-physical assets, and capex to operating cash flow, 392.20%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value61,558,860.56
Income Quality0.14
Sales General and Administrative to Revenue0.17
Research and Development to Revenue1.52%
Intangibles to Total Assets47.27%
Capex to Operating Cash Flow392.20%
Capex to Revenue-15.97%
Capex to Depreciation-109.99%
Stock-Based Compensation to Revenue0.91%
Graham Number2.70
Return on Tangible Assets-28.96%
Graham Net Net0.13
Working Capital8,076,000
Tangible Asset Value6,615,000
Net Current Asset Value4,410,000
Average Receivables3,879,000
Average Payables2,209,500
Average Inventory2,909,000
Days Sales Outstanding77
Days Payables Outstanding267
Days of Inventory On Hand212
ROIC-15.48%
ROE-0.22%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 4.40, and the price to book ratio, 4.40, reflect the market's valuation relative to the company's book value. The price to sales ratio, 6.31, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -31.66, and price to operating cash flows, -149.74, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio4.40
Price to Book Ratio4.40
Price to Sales Ratio6.31
Price Cash Flow Ratio-149.74
Price Earnings to Growth Ratio4.24
Enterprise Value Multiple-74.86
Price Fair Value4.40
Price to Operating Cash Flow Ratio-149.74
Price to Free Cash Flows Ratio-31.66
Price to Tangible Book Ratio3.13
Enterprise Value to Sales4.08
Enterprise Value Over EBITDA-47.28
EV to Operating Cash Flow-100.10
Earnings Yield-6.96%
Free Cash Flow Yield-4.74%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Optomed Oyj (OPTOMED.HE) on the HEL in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -20.168 in 2024.

What is the ticker symbol of Optomed Oyj stock?

The ticker symbol of Optomed Oyj stock is OPTOMED.HE.

What is company IPO date?

IPO date of Optomed Oyj is 2019-12-05.

What is company current share price?

Current share price is 5.360 EUR.

What is stock market cap today?

The market cap of stock today is 95281649.000.

What is PEG ratio in 2024?

The current 4.235 is 4.235 in 2024.

What is the number of employees in 2024?

In 2024 the company has 114.